Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2024-01-29 Proxy Solicitation & In…
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Management Information Circular and Notice of Special Meeting of Shareholders' for Kane Biotech Inc. It includes detailed information about the solicitation of proxies, voting procedures, record dates, and the agenda for a special shareholders meeting. The content focuses on governance matters such as the election of a director and proxy instructions, which are typical of materials provided to shareholders ahead of a meeting. There is no financial data, earnings information, or audit content. The document is not a report of voting results but rather the information circular and notice sent to shareholders to inform and solicit votes for the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed proxy solicitation information, not just a brief announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2024-01-29 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing a special meeting of shareholders to consider the election of a new director. It mentions the date of the meeting and that the information circular and other materials will be filed later. There is no financial data, no detailed report, no voting results, and no mention of an actual report being attached or published. The content focuses on board/management changes, specifically the election of a new director. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 4092 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-01-18 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for a Special Meeting of Security Holders of Kane Biotech Inc. It includes details such as the meeting date, record date for voting, and information about proxy materials. The document is short (1817 characters) and serves as an announcement of meeting logistics rather than containing any financial data, voting results, or detailed meeting materials. It does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement related to shareholder meeting logistics without substantive financial or voting content.
2024-01-04 English
News release - English.pdf
Regulatory Filings
2023-12-29 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an amendment to the company's credit facility, specifically extending the maturity date and changing interest payment terms. It discusses financing terms and agreements with a financial partner, Pivot I Financial Limited Partnership. There is no detailed financial data, quarterly or annual results, or management discussion of financial performance. The content focuses on financing activity and capital structure changes. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length is 4190 characters, which is consistent with a typical announcement rather than a full report. Hence, the classification is CAP with high confidence.
2023-12-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Kane Biotech has received a non-binding offer to sell its interest in STEM Animal Health. It discusses the strategic rationale for the transaction, terms of the offer, and an extension of a credit facility. There is no detailed financial data, no full financial report, no audit information, no voting results, no management or board changes, no earnings release, and no regulatory certification. The document is primarily an announcement of a transaction proposal and financing update. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a proposed sale of an asset and extension of a credit facility, both capital structure related updates. The document length is 5678 characters, which is sufficient for a substantive announcement but not a full report. Confidence is high given the clear transaction and financing content.
2023-12-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.